Fintel reports that on May 2, 2023, Baird maintained coverage of BeyondSpring (NASDAQ:BYSI) with a Outperform recommendation.
Analyst Price Forecast Suggests 168.42% Upside
As of April 24, 2023, the average one-year price target for BeyondSpring is 2.55. The forecasts range from a low of 1.01 to a high of $4.20. The average price target represents an increase of 168.42% from its latest reported closing price of 0.95.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for BeyondSpring is 1MM, a decrease of 9.40%. The projected annual non-GAAP EPS is -2.54.
What is the Fund Sentiment?
There are 43 funds or institutions reporting positions in BeyondSpring. This is a decrease of 10 owner(s) or 18.87% in the last quarter. Average portfolio weight of all funds dedicated to BYSI is 0.19%, an increase of 509.27%. Total shares owned by institutions decreased in the last three months by 85.07% to 1,060K shares. 
The put/call ratio of BYSI is 0.04, indicating a bullish outlook.
What are Other Shareholders Doing?
Millennium Management holds 194K shares representing 0.50% ownership of the company. In it's prior filing, the firm reported owning 344K shares, representing a decrease of 77.22%. The firm increased its portfolio allocation in BYSI by 0.14% over the last quarter.
Hennion & Walsh Asset Management holds 96K shares representing 0.25% ownership of the company. In it's prior filing, the firm reported owning 98K shares, representing a decrease of 2.35%. The firm increased its portfolio allocation in BYSI by 57,377.70% over the last quarter.
Group One Trading holds 61K shares representing 0.16% ownership of the company. In it's prior filing, the firm reported owning 46K shares, representing an increase of 24.61%. The firm increased its portfolio allocation in BYSI by 195.46% over the last quarter.
Jane Street Group holds 55K shares representing 0.14% ownership of the company. In it's prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.
Acadian Asset Management holds 46K shares representing 0.12% ownership of the company. No change in the last quarter.
BeyondSpring Background Information
(This description is provided by the company.)
BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring's lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.
See all BeyondSpring regulatory filings.This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
